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ABSTRACT
Interleukin-33 (IL-33) is a member of the IL-1 cytokine family, which includes IL-1 and IL-18. IL-33 is considered
to be crucial for induction of Th2-type cytokine-associated immune responses such as host defense against
nematodes and allergic diseases by inducing production of such Th2-type cytokines as IL-5 and IL-13 by Th2
cells, mast cells, basophils and eosinophils. In addition, IL-33 is involved in the induction of non-Th2-type acute
and chronic inflammation as a proinflammatory cytokine, similar to IL-1 and IL-18. In this review, we summarize
and discuss the current knowledge regarding the roles of IL-33 and IL-33 receptors in host defense and dis-
ease development.
KEY WORDS
allergy, autoimmunity, basophil, chronic disease, eosinophil, host defense, IL-33, mast cell, ST2
REDISCOVERY OF IL-33
Interleukin-33 (IL-33) was originally identified as
“DVS27,” a gene which was upregulated in vasospas-
tic cerebral arteries after subarachnoid hemorrhage,1
and as a “nuclear factor from high endothelial ve-
nules (NF-HEV),” which is expressed in endothelial
cell nuclei.2 In 2005, DVS27 was rediscovered as IL-
33 by using computational tools to search for se-
quences containing the β-trefoil structure seen in IL-
1- and FGF-like proteins. IL-33 (also called IL-1F11) is
now regarded as the 11th member in the IL-1 family of
cytokines, which includes IL-1α, IL-1β and IL-18.3 Ex-
pression of IL-33 mRNAprotein is observed in vari-
ous organs and types of cells (Table 1). In the litera-
ture, relatively high levels of IL-33 mRNA expression
are observed in the brain and spinal cord of mice.3
IL-33 AS A NUCLEAR FACTOR
IL-33 has the closest amino acid sequence homology
to IL-18 among the members of the IL-1 cytokine fam-
ily.3 In striking contrast to the other IL-1-related cy-
tokines except for IL-1α, IL-33 is localized in the nu-
cleus of human epithelial and endothelial cells2 and
mouse bone-marrow derived cultured mast cells
(BMCMCs)4 by binding to chromatin via a homeodo-
main (helix-turn-helix-like motif) and nuclear localiza-
tion signal in its amino-terminus (Fig. 1).5,6 Although
the pathophysiological role of IL-33 as a nuclear fac-
tor is not fully understood, IL-33 is known to bind to
the acidic pocket of a dimeric histone, H2A-H2B, on
the surface of nucleosomes, resulting in suppression
of gene transcription, at least in the in vitro reporter
assay system.6
IL-33 RECEPTOR AND SIGNAL TRANSDUC-
TION
Schmitz et al. first identified the orphan receptor
“ST2” (also called IL-1R4) as a receptor for IL-33.3 As
in the case of receptors for the other IL-1-related cy-
tokines, IL-33 receptor (IL-33R) is formed from het-
erodimeric molecules, consisting of ST2 and IL-1R ac-
cessory protein (IL-1RAcP).7,8 IL-1RAcP is a shared
component of receptors for IL-1α, IL-1β, IL-1F6, IL-
1F8 and IL-1F9.9-11 In this review, the complex of ST2
and IL-1RAcP is designated as “IL-33R1.”
Two major products of ST2 genes (transmembrane
form ST2 [ST2 or ST2L] and soluble form ST2
[sST2]) are produced by alternative splicing under
the control of two distinct promoters.12 In addition,
ST2LV and sST2V, which are other splicing variants
for ST2L and sST2, respectively, have also been iden-
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Fig. 1 IL-33, a 270-amino-acid protein, consists of two 
domains: a homeodomain and a cytokine (IL-1-like) domain. 
The homeodomain contains a nuclear localization signal 
(NLS).
IL-33 (DVS-27, NF-HEV)
N-
Helix-turn-helix domain
(Homeodomain-like)
+
NLS
IL-1-like domain
-C
Fig. 2 IL-33 binds to IL-33 receptor, which is a dimer of 
ST2 and IL-1RAcP. The TIR-domain of IL-33 receptor re-
cruits MyD88 and TRAF6, and the receptor signal results in 
activation of NF-kB or AP-1.
MAPK
TAK1
NIK
IL-33
IRAK1
IRAK4
ST2 IL-1RAcP
TIR-domain
NF-kB activation AP1 activation
IKK
MyD88
T
R
A
F
6
tified in chickens and humans.13,14 ST2 is considered
to be the functional component for induction of IL-33
bioactivities, while sST2 acts as a decoy receptor for
IL-33, similar to soluble IL-1Rs for IL-1.9-11
The signal transduction downstream of IL-33R1 is
mediated by adapter molecules that are shared by
other IL-1 receptor family members such as IL-1R
and IL-18R. The binding of IL-33 to IL-33R1 results in
recruitment of MyD88 to the Toll-interleukin-1 recep-
tor (TIR) domain in the cytoplasmic region of ST2,
leading to induction of inflammatory mediators by ac-
tivating transcription factors such as NF-κB and AP-1
through IRAK, TRAF6 andor MAP kinases (Fig. 2).3
Recently, it has been shown that IL-33 binds to an-
other IL-33R different from IL-33R1. In addition to IL-
1RAcP, ST2 forms a complex with another IL-1R fam-
ily molecule, “single Ig IL-1R-related molecule
(SIGIRR) (also called Toll IL-1R8 [TIR8])”.15 In this
review, the complex of ST2 and SIGIRR is designated
as “IL-33R2”. SIGIRRTIR8 is considered to act as a
negative regulator for IL-1R- and Toll-like receptor
(TLR)-mediated immune responses. 16 Indeed,
SIGIRRTIR8-deficient dendritic cells showed hyper-
responsiveness to stimulation with IL-1, IL-18 and
TLR agonists.17 In addition, SIGIRRTIR8-deficient
Th2 cells showed augmented Th2-type cytokine pro-
duction in response to IL-33.15 In contrast to IL-33R1
(ST2IL-1RAcP), IL-33R2 seems to act as a negative
regulator of IL-33.
TARGET CELLS OF IL-33
Th2 CELLS
It is well established that IL-4 is a key cytokine for the
differentiation of Th2 cells from naïve CD4+ T cells.
ST2 is predominantly expressed on Th2 cells but not
naïve T cells, Th1 cells, Th17 cells or regulatory T
cells.18-20 On the other hand, ST2 is not essential for
Th2 cell differentiation, as shown in studies using
ST2-deficient mice: ST2-deficient mice showed nor-
mal development of Th2 cells.21,22 In support of that,
although IL-33 did not induce differentiation of Th2
cells from naïve CD4+ T cells in vitro,23,24 it enhanced
IL-5 and IL-13, but not IL-4, production by in vitro-
skewed Th2 cells which highly express ST2.3,7,23,25,26
In humans, IL-33 potentiates not only Th2-type cy-
tokine production but also production of a Th1-type
cytokine, IFN-γ, by peripheral blood-derived Th2
cells,27 although IFN-γ production is only slightly in-
creased by peripheral blood-derived human Th1
cells.26 In addition, IL-33 acts as a chemoattractant for
Th2 cells, but not Th1 cells, in both humans and
mice.28
In contrast to the role of IL-33 in Th2 cell differen-
tiation, Kurowska-Stolarska et al. reported that IL-33
induces differentiation of IL-5-positive IL-4-negative
CD4+ T cells (IL-5+IL-4- Th cells) from naïve CD4+ T
cells independently of IL-4, STAT-6 and GATA-3,
which are important factors for the typical Th2 cell
differentiation.24 While ST2-expressing Th cells are
also observed in IL-4-, IL-5- or IL-10-deficient
mice,19,29 two distinct populations of IL-4-producing
Th cells were found: ST2-positive Th2 cells, which
produce IL-4, IL-5 and IL-10, and ST2-negative Th2
cells, which produce IL-4 and IL-10, but not IL-5, in
mice during Leishmania major infection.30 Further
evidence regarding the role of IL-33 in the differentia-
tion of typical and atypical Th2 cells may provide new
insight into the molecular mechanisms in Th2-type
cytokine-mediated disorders such as allergic asthma.
In addition to CD4+ Th2 cells, it has been shown
that type II CD8+ cytotoxic T cells (Tc2 cells) and IL-
10-producing Tr1 cells also express ST2 on their cell
surface.31,32 However, the precise roles of IL-33 in
Tc2 and Tr1 cells remain unclear.
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MAST CELLS (MCs)
MCs, which express c-Kit and high-affinity IgE recep-
tors (FcεRI) and are predominantly localized in mu-
cosal and connective tissues, are major effector cells
in the induction of IgE-mediated immune responses.
After binding of antigens (Ags) to IgE-bearing MCs
via FcεRI, MCs rapidly release a large variety of in-
flammatory mediators from their granules, thereby
provoking local and systemic inflammation. Mouse
MCs (i.e., BMCMCs and connective tissue-type MCs
from the peritoneal cavity) and MCbasophil precur-
sor cells and human MCs (i.e., cord blood and pe-
ripheral blood stem cell-derived cultured MCs) con-
stitutively express ST2.33-36 Except for IL-3 and stem
cell factor (SCF, a ligand for c-kit), which are re-
quired for mast cell development at least in mice, IL-
33 is the only cytokine among 45 different cytokines
which can directly induce cytokine and chemokine
(IL-1β, IL-6, IL-13, TNF and MCP-1) secretion from
mouse BMCMCs without effecting their degranula-
tion.37,38 Like its murine counterpart, human IL-33
can induce cytokine and chemokine production, pro-
long survival and promote cell-adhesion in human
cord blood stem cell-derived cultured MCs.35,36 In ad-
dition, IL-33 can augment IgE-mediated cytokine pro-
duction and degranulation by mouse BMCMCs and
or human cord blood stem cell-derived cultured
MCs.35-37,39 IL-33-mediated cytokine production by
mouse BMCMCs and human cord blood stem cell-
derived cultured MCs is enhanced in the presence of
IL-3 and thymic stromal lymphopoietin (TSLP), re-
spectively.23,36
Although the levels of phorbol ester + ionophore-
induced IL-4 production and IgE + antigen-mediated
histamine release from ST2-deficient BMCMCs are
comparable to those from wild-type BMCMCs,21 ST2-
deficient BMCMCs do not produce cytokines in re-
sponse to IL-33.23 Therefore, IL-33-induced mast cell-
derived cytokines are not involved in IL-4 production
or IgE-dependent histamine release.
BASOPHILS
Basophils, which express FcεRI, but not c-Kit, on
their cell surface, are considered to be a potential pri-
mary source of IL-4 in certain allergic immune re-
sponses.40,41 Supporting this, it was recently reported
that basophils express MHC class II and present Ags
to naïve T cells as an Ag-presenting cell, inducing Ag-
specific Th2 cell differentiation in lymph nodes that is
dependent on IL-4 production and Ag-presentation by
activated basophils.42-44
In comparison with Th2 cells and MCs, human and
mouse basophils constitutively express ST2 at a rela-
tively low level on their cell surface.23,26,45,46 On the
other hand, expression of ST2 on the cell surface of
basophils is promoted by stimulation with IL-3.26 Like
the effect of IL-33 on Th2 cells and MCs, IL-33 alone
can induce production of cytokines, including Th2-
type cytokines, and chemokines by basophils and
promote cell-adhesion and CD11b expression by hu-
man and murine basophils.26,27,45,46 IL-33 does not in-
duce degranulation of basophils directly, but it syner-
gistically enhances IgE-mediated degranulation of hu-
man basophils.26,45 In addition, IL-33 augments im-
mune responses of human and murine basophils in
humans and mice: eotaxin-mediated migration,45 cy-
tokine secretion in the presence of IL-3, which is a
growth factor for basophils as well as mast
cells,23,26,27,45-47 and prolonged survival in the pres-
ence of IL-3 or GM-CSF.45-47 These observations sug-
gest that IL-33 is a potential activator of basophils by
enhancing their cytokine and chemokine secretion,
recruitment and adhesion.
EOSINOPHILS
Eosinophilia is found in local inflammatory sites in pa-
tients with certain IgE-mediated allergic disorders,
such as asthma. Although ST2 expression was barely
detectable on the cell surface of human peripheral
blood eosinophils, ST2 mRNA and intracellular ST2
protein were detectable in them.26,48,49 IL-33 can di-
rectly induce production of superoxide and IL-8 and
enhance IL-3-, IL-5- or GM-CSF-mediated IL-8 produc-
tion by human eosinophils.26,48 As in the case of MCs
and basophils, IL-33 enhances adhesion of eosino-
phils by promoting CD11b expression and survival in-
dependently of IL-4, IL-5 and GM-CSF.49 Unlike the
case of basophils, IL-33 does not influence eotaxin-
mediated migration of eosinophils.49 The role of IL-33
in the degranulation of eosinophils remains contro-
versial. One group demonstrated that IL-33 alone
could enhance degranulation (EDN release) of hu-
man eosinophils,48 whereas another showed that IL-
33 could not (assessed by EDN and LTC4 release).49
These observations strongly suggest that IL-33 may
contribute to the pathogenesis of certain allergic dis-
orders accompanied by marked accumulation of
eosinophils.
NATURAL KILLER (NK) CELLS AND NKT CELLS
As in the case of Th2 and Tc2 cells, ST2 expression
was observed on the cell surface of IL-4-producing
NK cells (NK2 cells), but not IFN-γ-producing NK
cells (NK1 cells), which were derived in vitro from a
freshly-isolated NK cell population of human PBMCs
under Th1Th2 cytokine-skewed culture condi-
tions.31 Smithgall et al. demonstrated that freshly-
isolated NK cells from human PBMCs could produce
IFN-γ in response to IL-33 in the presence, but not ab-
sence, of IL-12 or IL-23, since IL-12 andor IL-23 en-
hanced the expression of ST2 mRNA in NK cells.27
However, that study did not elucidate the role of IL-33
in Th2-type cytokine secretion by NK cells.
Smithgall et al. also detected ST2 mRNA expres-
sion in human invariant NKT (iNKT) cells and dem-
onstrated a role for IL-33 in these cells: IL-33 en-
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hanced TCR-dependent cytokine production (i.e.,
IFN-γ, IL-2, IL-4, IL-5, IL-13 and TNF) by iNKT cells
after stimulation with α-galactosylceramide (α-
GalCer).27 Moreover, IL-33 enhanced IFN-γ, but not
IL-4, production by iNKT cells in the presence, but
not absence, of IL-12, independently of TCR stimula-
tion.27 As in the case of NK cells, IL-12 enhances ST2
mRNA expression in human iNKT cells.27
Administration of IL-33 to mice results in increased
expansion of iNKT cells in the spleen and liver.50
Thymic iNKT cells constitutively express ST2 on
their cell surface, and IL-33 enhances IL-7-mediated
thymic iNKT cell proliferation.50 IL-33 alone could not
induce cytokine secretion by naïve mouse iNKT cells.
On the other hand, similar to the study in human
iNKT cells,27 IL-33 enhanced both IL-4 and IFN-γ pro-
duction by TCR-stimulated mouse iNKT cells and
IFN-γ, but not IL-4, production by mouse iNKT cells
in the presence of IL-12, independently of TCR stimu-
lation.50 In contrast to the findings for human iNKT
cells,27 IL-12 could not enhance ST2 expression in
mouse iNKT cells. These observations suggest that
IL-33 may have a non-Th1Th2 cytokine-restricted
role in certain NK cell- and NKT cell-mediated im-
mune responses.
DENDRITIC CELLS (DCs)
IL-33 is considered to promote the development of
DCs from bone marrow cells.51 It has been shown
that DCs derived by cultivation of murine bone mar-
row cells in the presence of GM-CSF and IL-4 (that is,
bone marrow-derived DCs; BMDCs) express ST2.52
IL-33 enhances the production of IL-6, but not IL-12,
by BMDCs and augments the expression of MHC
class II and CD86, but not CD80, CD40 and “OX40
ligand (OX40L)”, on the cell surface of BMDCs.52
When naive CD4+ T cells were co-cultured with
BMDCs in the presence of IL-33 for 6 to 10 days, IL-5
and IL-13, but not IL-4 or IFN-γ, were detected in the
culture supernatant even without TCR engagement.
Since such cytokine secretion was not induced by IL-
33 in the culture of naïve CD4+ T cells alone, the ef-
fect of IL-33 seemed to be mediated by factors de-
rived from IL-33-stimulated BMDCs through a TCR
Ag-MHC class II-independent pathway. However, the
secreted cytokine profiles (IL-5 and IL-13, but not IL-
4, production) in the setting (BMDCs + naïve CD4+ T
cells + IL-33, no Ag) are similar to those by the IL-5-
positive, IL-4-negative atypical Th2 cell population ob-
served in the culture of naïve CD4+ T cells stimulated
by TCR engagement plus IL-33, as described above.
Thus, these observations suggest that IL-33 can en-
hance induction of an IL-5-positive, IL-4-negative
atypical Th2 cell population from naïve CD4+ T cells
directly andor indirectly from DCs via the effects of
certain factors.
Like IL-33, IL-25 and TSLP are known to be Th2-
prone cytokines and contribute to the induction of
Th2-type cytokine-mediated immune responses.53 In
contrast to the case of IL-33, TSLP-activated DCs pro-
mote IL-4-producing Th2 cell differentiation from
naïve CD4+ T cells in the presence of TCR engage-
ment through OX40L-OX40 interaction, at least in
part.54,55 IL-25 can enhance TSLP-stimulated DC-
mediated Th2 cell expansion.56 Unlike IL-33, both
TSLP and IL-25 can induce differentiation of IL-4-
producing Th2 cells from naïve CD4+ T cells after
TCR engagement, dependent on the IL-4-IL-4Rα-
STAT6 pathway.57,58 Therefore, these observations
suggest that the roles of IL-33, TSLP and IL-25 in T
cells and DCs may be different in Th2-type cytokine-
mediated immune responses. That is, TSLP and IL-25
may be preferentially involved in the induction of
antigen-specific IL-4IL-5IL-13-producing Th2 cell-
mediated immune responses, while IL-33 may con-
tribute, at least in part, to the induction of antigen-
non-specific Th2 cell-mediated immune responses by
inducing IL-5IL-13-, but not IL-4-, and thereby pro-
ducing atypical Th2 cells.
MACROPHAGES
Constitutive expression of ST2 mRNAproteins was
detected in mouse bone marrow cell-derived cultured
macrophages and mouse alveolar macrophage cell
lines.59,60 Soluble ST2 expression was increased in
macrophages in response to LPS and proinflamma-
tory cytokines such as TNF, IL-1 and IL-6.60-62 IL-33
promoted the expression of LPS receptor compo-
nents, such as MD2, TLR4, soluble CD14 and
MyD88.63 Although IL-33 alone did not induce TNF,
IL-1 or IL-6 production by thioglycolate-induced
mouse peritoneal macrophages, it did in the presence
of LPS.63 Such effects of IL-33 on LPS-mediated acti-
vation were abolished in anti-ST2 Ab-treated and ST2-
deficient macrophages. Therefore, IL-33 may be a po-
tential activator of macrophages during bacterial in-
fections.
In addition, both naïve and thioglycolate-induced
mouse peritoneal macrophages produced IL-33 upon
LPS stimulation,4 suggesting that macrophage-
derived IL-33 may autocrinely enhance LPS-mediated
macrophage activation. Supporting this, LPS-
mediated production of cytokines, such as IL-1, IL-6,
IL-12 andor TNF, by mouse bone marrow cell-
derived cultured macrophages or mouse alveolar
macrophage cell lines was inhibited by addition of
soluble ST2-Fc fusion proteins.59,60
It is well known that macrophages are key effector
cells during septic shock. It was shown that mice
treated with polyclonal anti-ST2 antiserum, which had
potential activity to deplete ST2-expressing cells, in-
cluding macrophages,64 were highly susceptible to
LPS-induced endotoxin shock,59 suggesting the im-
portance of ST2-expressing macrophages for protec-
tion against this event. Consistent with the effect of
soluble ST2-Fc fusion proteins on macrophage activa-
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tion by LPS, mice treated with soluble ST2-Fc fusion
proteins were resistant to endotoxin shock and
showed reduced serum IL-6 and TNF levels after in-
traperitoneal LPS injection.59
However, in contrast with the effect of soluble ST2-
Fc fusion proteins,59,60 IL-6, IL-12 and TNF produc-
tions by ST2-deficient thioglycolate-induced perito-
neal macrophages were increased in response to
LPS.65 In addition, ST2-deficient mice showed high
susceptibility to LPS-induced endotoxic shock.65 The
apparent discrepancy between the results using
macrophages treated with soluble ST2-Fc fusion pro-
teins and macrophages deficient in ST2 may be ex-
plained as follows. Perhaps ST2-deficiency results in
increased formation of other IL-1R family molecules,
such as IL-1R (IL-1R1 and IL-1RAcP), due to the fail-
ure of formation of IL-33R1 (ST2 and IL-1RAcP), caus-
ing cytokine hyperproduction by ST2-deficient
macrophages in response to IL-1, which can be pro-
duced by these macrophages after LPS stimulation.
Indeed, ST2-deficient macrophages produced larger
amounts of cytokines than wild-type macrophages af-
ter IL-1β treatment.65 Although IL-1R1-deficient mice
showed normal susceptibility to LPS-induced endo-
toxic shock,66 IL-1R antagonist-deficient mice, which
have excessive IL-1-signaling, showed high suscepti-
bility.67 This suggests that IL-1 is not required for in-
duction of LPS-induced endotoxic shock, but exces-
sive IL-1 production leads to amplified susceptibility
to LPS, as seen in ST2-deficient mice.
Macrophages are phenotypically divided into two
distinct populations: “classically activated macro-
phages (CAMφ)type 1 macrophages (M1)” and “al-
ternatively activated macrophages (AAMφ)type 2
macrophages (M2).” CAMφM1s are generated in re-
sponse to IFN-γ and LPS (or TNF induced by bacte-
rial components) and are involved in Th1-type im-
mune responses such as host defense against viral
and bacterial infections and tumor rejection by pro-
ducing IL-12, IL-23 and nitric oxide. M2 macrophages
are further subdivided into at least three populations
by in vitro stimulation with distinct factors: IL-4- and
or IL-13-stimulated M2a (also called AAMφ), immune
complex plus IL-1β- or LPS-stimulated M2b (also
called typeIIMφ) and IL-10-, TGF-β- or glucocorticoid-
treated M2c (also called deactivated Mφ).68-71
IL-13 enhances ST2 expression in mouse bone
marrow cell-derived cultured macrophages, and IL-33
amplifies polarization of M2aAAMφs in the pres-
ence, but not absence, of IL-13, contributing to the in-
duction of Th2-type immune responses.72
CD34-POSITIVE HEMATOPOIETIC PROGENITOR
CELLS
CD34+ hematopoietic progenitor cells are capable of
differentiating into various types of cells in the bone
marrow and peripheral tissues. Recently, it was
shown that mRNA and cell surface expression of ST2
as well as TSLPR were found in CD34+ hematopoietic
progenitor cells derived from human umbilical cord
blood cells.73 IL-33 enhances the production of vari-
ous cytokines and chemokines, including IL-5, IL-13,
CCL17 and CCL22, by human umbilical cord blood
cell-derived CD34+ hematopoietic progenitor cells in
cooperation with TSLP in the presence of IL-3 and
SCF.73 Interestingly, the number of CD34+ hema-
topoietic progenitor cells was increased in peripheral
blood from allergic patients.73 In addition, IL-5- and
IL-13-producing CD34+ hematopoietic progenitor
cells were also detected in sputum from patients with
asthma. These observations suggest that CD34+ he-
matopoietic progenitor cells may themselves be po-
tential effector cells by responding to IL-33 and TSLP
even in the undifferentiated state and contributing to
the development of allergic diseases.
NATURAL HELPER CELLS
Adipose tissue-associated Lin- c-Kit+ Sca-1+ natural
helper cells are a newly identified population distinct
from lymphoid progenitors and lymphoid tissue in-
ducer cells.74 Natural helper cells constitutively ex-
press ST2 and can produce larger amounts of IL-5
and IL-13 than basophils and mast cells in response
to IL-33. IL-33-mediated natural helper cell activation
was shown to be important for development of goblet
cell hyperplasia during Nippostrongylus brasiliensis in-
fection.74
PRODUCERS AND RELEASE OF IL-33 AS
“Alarmin”
During host defense against pathogens, innate im-
mune cells recognize pathogen-associated molecular
patterns (PAMPs) directly via Toll-like receptors
(TLRs), resulting in induction of local andor sys-
temic inflammation. In addition, endogenous proin-
flammatory factors called “damage associated mo-
lecular patterns (DAMPs)” (also called “alarmin”),
which are released by necrotic cells in injured tissues
during trauma andor infection, also provoke local
andor systemic inflammation by acting as an endo-
genous danger signal that often promoting immune
responses.75 For example, high-mobility group box 1
(HMGB1), which was initially identified as a nuclear
factor acting as a transcriptional regulator, is released
by macrophages in response to LPS, leading to induc-
tion of inflammation.76 Like HMGB1, several recent
lines of evidence suggest that IL-33, which is also lo-
calized in the nucleus, may also act as a DAMP
alarmin.77
As noted earlier, Schmitz et al. demonstrated that
IL-33 shows the closest amino acid sequence homol-
ogy to IL-18 among the members of the IL-1 family of
cytokines.3 Like IL-1β and IL-18, IL-33 is not consid-
ered to be secreted via the conventional vesicle trans-
port pathway because its amino-terminus lacks the
necessary signal sequence. Also like IL-1β and IL-18,
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Fig. 3 Modes of cel death and IL-33 release. IL-33 is thought to be passively released 
by necrotic cels. On the other hand, caspases cleave IL-33, resulting in inactivation of IL-
33 during apoptosis.
Epithelium
Endothelium
Necrosis
Apoptosis
Active IL-33
Inactive IL-33
Caspase-3, -7
it was reported that IL-33 was cleaved from pro-IL-33
by caspase-1 in vitro,3 suggesting that IL-33 may be
secreted by activation of NACHT, LRR and PYD-
containing protein (NLRP)-mediated inflammasomes.
However, pro-IL-33 does not have a typical cleavage
site such as seen in pro-IL-1β and pro-IL-18, and
caspase-1 proteolytically cleaved pro-IL-33 in the cy-
tokine motif, not the intermediate region between the
helix-turn-helix and cytokine motifs, resulting in inac-
tivation of IL-33.77-79 Like caspase-1, both caspase-3
and caspase-7 are able to cleave pro-IL-33 during
apoptosis, although apoptotic cells do not generally
induce inflammation, and IL-33 processed by these
caspases does not express biological activities via IL-
33R1 (Fig. 3).77,78 On the other hand, it is known that
pro-IL-33 is released by necrotic cells without any
processes by proteases such as caspase-1, -3, -7 and -8
andor calpain.4,77-79 In addition, like pro-IL-1α, pro-
IL-33 has biological activity78: pro-IL-33 can induce
mouse mast cell activation so that they produce cy-
tokines via IL-33R1.79 Therefore, these observations
suggest that pro-IL-33 released by necrotic cells dur-
ing tissue injury may play a DAMPalarmin-like role
in induction of inflammation. However, it remains un-
clear whether IL-33 can act as a potent adjuvant pro-
foundly promoting acquired immune responses com-
pared to other alarmin adjuvants such as ATP which
are also released during necrosis.
IL-33-IL-33R IN INFECTIONS
LEISHMANIA MAJOR
It is well established that host protection against a
protozoan, Leishmania major, is mediated by Th1
cell-mediated immune responses, but reciprocally ag-
gravated by Th2 cell-mediated immune responses.80
ST2-expressing CD4+ T cells accumulate in local le-
sions of L. major-infected mice.81 Administration of
polyclonal anti-ST2 antiserum, which has potential ac-
tivity to-deplete ST2-expressing cells, including Th2
cells, reduced lesion development and Th2 cytokine
production and increased Th1 cytokine production
during L. major infection in female BALBc mice, a
strain that is susceptible to this pathogen.64 On the
other hand, BALBc mice treated with anti-ST2 mAb
(clone DJ8), which did not deplete ST2-expressing
cells, or ST2-Fc fusion proteins showed lesion devel-
opment, parasite replication and antigen-specific ST2+
Th2 cell differentiation that were similar to in mice
treated with control Ab, although their IFN-γ produc-
tion was increased.30 These observations suggest that
ST2-expressing immune cells, but not IL-33-ST2-
mediated signaling, contribute to the pathogenesis of
leishmaniasis in mice.
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TOXOPLASMA GONDII
Th1-type cytokine-associated immune responses are
important for protection against another protozoan,
Toxoplasma gondii.82 ST2 mRNA expression was
upregulated, but IL-33 mRNA expression was not al-
tered, in brain lesions of mice infected with T. gondii
compared with naïve mice.83 ST2-deficient mice
showed high susceptibility to T. gondii in comparison
with wild-type BALBc mice.83 On the other hand,
susceptibility to this protozoan was similar in wild-
type, IL-4-deficient and IL-4Ra-deficient mice.83 These
observations suggest that the IL-33-IL-33R pathway is
important for protection against T. gondii, independ-
ently of IL-4 and IL-13 production.
NIPPOSTRONGYLUS BRASILIENSIS
Th2-type cytokines are important for protection
against Nippostrongylus brasiliensis and Trichinella
spiralis, nematode parasites.84 However, IL-4 produc-
tion by splenic CD4+ T cells and the serum levels of
total IgG1 and IgE were normal in ST2-deficient mice
on the 129 x B6 mixed background after N. brasilien-
sis infection.21,85 On the other hand, the proportion of
IL-5-producing CD4+ T cells and the number of
eosinophils in the lung were decreased in ST2-
deficient mice on the 129 x B6 mixed background
during N. brasiliensis infection, although the eggs of
this parasite were normally cleared in these mutant
mice.85 These observations suggest that the IL-33-IL-
33R pathway contributes to eosinophilia induced by
N. brasiliensis infection, but is dispensable for protec-
tion against parasitic nematodes.
SCHISTOSOMA MANSONI
Th2 cells are considered to be key effector cells in
the immune responses to a helminth parasite, Schis-
tosoma mansoni.86,87 ST2-deficient mice on the 129 x
B6 mixed background showed impaired granuloma
formation, characterized by eosinophil infiltration, in
the lungs after the first S. mansoni egg injection.22 On
the other hand, these mutant mice, which had been
sensitized with S. mansoni eggs, showed normal pul-
monary granuloma formation and serum IgG1 and
IgE levels after the second egg challenge, although
they showed reduced IL-4 and IL-5 production by me-
diastinal lymph node cells in response to S. mansoni
egg antigens.22 These observations suggest that the
IL-33-IL-33R pathway is involved in Th2 cytokine pro-
duction but not antibody production during infection
with S. mansoni.
TRICHURIS MURIS
It is also known that Th2-type cytokines are important
for protection against a parasitic nematode, Trichuris
muris.88 During T. muris infection in mice, it was
shown that IL-33 mRNA expression was increased in
the cecum,89 suggesting a contribution of IL-33 to
host defense against T. muris. Indeed, administration
of IL-33 to AKR mice, but not SCID mice, resulted in
accelerated parasite clearance during T. muris infec-
tion.89 Although T cells andor B cells are required
for IL-33-mediated parasite expulsion, as seen in
SCID mice during T. muris infection, IL-33 induced
pathological changes such as increased crypt length
and intestinal epithelial cell proliferation independ-
ently of T cells andor B cells.89 In those settings, NK
cells were increased in mesenteric lymph nodes of IL-
33-injected, T. muris-infected SCID mice, suggesting
a contribution of NK cells to the TB cell-
independent IL-33-mediated pathological changes
during T. muris infection.
PSEUDOMONAS AERUGINOSA
ST2 mRNAprotein and IL-33 mRNA expression were
increased in local inflammatory lesions infected with
a gram-negative bacterium, Pseudomonas aerugi-
nosa.90,91 Administration of soluble ST2 to mice re-
sulted in aggravation of the keratitis induced by P.
aeruginosa,90 suggesting that the IL-33-IL-33R path-
way is important for protection against P. aeruginosa.
MYCOBACTERIUM TUBERCULOSIS
It is known that both Th1 and Th17 cytokines are cru-
cial for defense against a bacterium, Mycobacterium
tuberculosis.92 Even though PPD-specific IFN-γ pro-
duction was increased in the culture supernatants of
spleen cells from M. tuberculosis-infected ST2-
deficient mice, the survival, bacterial counts, granu-
loma formation and pulmonary inflammation score
were comparable between ST2-deficient and -suffici-
ent mice during M. tuberculosis infection.93 On the
other hand, SIGIRRTIR8-deficient mice showed
high susceptibility to M. tuberculosis infection.94
These observations suggest that the IL-33-IL-33R1
pathway is not crucial for M. tuberculosis pathogene-
sis, while the IL-33-IL-33R2 pathway is important for
host defense against this pathogen.
LEPTOSPIRA
It was shown that the level of soluble ST2 was in-
creased in plasma from patients with leptospirosis
due to a gram-negative Leptospira infection and was
associated with the severity of the disease, bleeding
and mortality, suggesting a contribution of the IL-33-
IL-33R pathway to the pathogenesis of leptospirosis.95
However, the precise role of the IL-33-IL-33R pathway
in this disease remains unclear.
VIRUSES
The serum levels of soluble ST2 protein were in-
creased in patients infected with dengue virus.96 In
mice, IL-33 was increased in the brain after infection
with Theiler’s murine encephalomyelitis virus.97
These observations suggest a contribution of the IL-
33-IL-33R pathway to the pathogenesis of certain viral
infections.
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Inhalation of respiratory syncytial virus (RSV) by
mice that had been sensitized with recombinant vac-
cinia virus expressing the attachment protein G of
RSV resulted in induction of Th2-type cytokine-
associated eosinophilic airway inflammation. On the
other hand, inhalation of RSV by mice sensitized with
recombinant vaccinia virus expressing the fusion pro-
tein F of RSV led to induction of non-eosinophilic air-
way inflammation. In this model, administration of
anti-ST2 mAb (clone 3E10) attenuated the develop-
ment of Th2-type cytokine-associated eosinophilic air-
way inflammation, but not non-eosinophilic airway in-
flammation.98 These observations suggest that the IL-
33-IL-33R pathway is crucial for the development of
virus-induced, Th2-type cytokine-associated eosino-
philic inflammation.
IL-33-IL-33R IN ANGIOGENESIS AND TU-
MORGENESIS
IL-33 is constitutively expressed in nuclei of vascular
endothelial cells in various human tissues such as the
skin, small intestine, umbilical veins and lungs.99 On
the other hand, constitutive expression of IL-33 was
not observed in human angiogenic tumor vessels.99
Induction of IL-33 was observed during confluent
growth of endothelial cells. On the other hand, ex-
pression of IL-33 was down-regulated during migra-
tion of those cells. Expression of nuclear IL-33 was
rapidly down-regulated at the onset of angiogenesis
during wound healing.99 Proinflammatory cytokines
(e.g., IL-1β and TNF) and proangiogenic growth fac-
tors (e.g., VEGF), which are induced during wound
healing, suppressed IL-33 expression in endothelial
cells.99 In addition, IL-33 promoted angiogenesis by
promoting proliferation, migration and differentiation
of endothelial cells, and vascular permeability by re-
ducing cell-cell interactions via cadherin.100 These ob-
servations suggest that IL-33 may be involved in tu-
morigenesis and the development of vascular dis-
eases.
IL-33-IL-33R IN ALLERGIC DISEASES
ASTHMA
The levels of soluble ST2 protein and IL-33 mRNA
protein are increased in sera and tissues from pa-
tients with asthma.27,72,101-103 Genome-wide associa-
tion studies identified polymorphism in the ST2 and
or IL-33 genes in patients with asthma, suggesting an
association with susceptibility to asthma.104-106 In sup-
port of that notion, intraperitoneal or intranasal ad-
ministration of IL-33 to mice led to induction of
eosinophilic inflammation in the pulmonary and intes-
tinal mucosa through the IL-13 and STAT6-dependent
pathway.3,23
The levels of soluble ST2 protein and IL-33 mRNA
were increased in sera andor lungs in a murine
asthma model of airway inflammation induced by
ovalbumin (OVA).107,108 However, the roles of ST2
and IL-33 in the induction of OVA-induced airway in-
flammation in mice remain controversial. Respiratory
function, airway pathology, eosinophil number in
bronchoalveolar lavage fluids (BALFs) andor the
levels of serum total IgG1 and IgE were normal in
129 × B6 mixed and BALBc background-ST2-
deficient mice sensitized twice with OVA emulsified
with alum (Table 2).21,24,109 On the other hand, airway
inflammation was attenuated in BALBc background-
ST2-deficient mice sensitized once with OVAalum
(Table 2).24 Moreover, it is noteworthy that OVA-
induced airway inflammation was exacerbated in SI-
GIRRTIR8-deficient mice.15
Several investigators reported the effect of an anti-
ST2 mAb (clone 3E10) on OVA-induced airway in-
flammation in BALBc mice (sensitized twice with
OVAAlum). That mAb enhanced ST2-expressing
Th2 cell proliferation and cytokine production in vi-
tro, indicating that it acts as an agonistic Ab, at least
on Th2 cells.110 Despite its agonistic activity on Th2
cells in vitro, BALBc mice treated with 3E10 mAb
showed attenuated airway inflammation in response
to OVA (Table 3).111,112 Likewise, Th2 responses dur-
ing OVA-induced airway inflammation (sensitized
twice with OVAAlum) were reduced in mice carry-
ing a soluble ST2 gene expression vector or treated
with an anti-IL-33 polyclonal Ab (Table 3).107,113
Adoptive transfer with in vitro-skewed DO11.10
Th2 cells, which express OVA-specific T-cell recep-
tors, in mice resulted in Th2 cytokine-dependent
eosinophilic airway inflammation after intranasal
OVA challenge.114 BALBc wild-type mice or BALB
c-Rag-1-deficient mice injected with ST2-deficient
DO11.10 Th2 cells showed exacerbated airway func-
tion and inflammation after OVA challenge in com-
parison with mice injected with ST2-sufficient
DO11.10 Th2 cells (Table 4).109 These observations
suggest that IL-33 signals on Th2 cells have a regula-
tory function in OVA-induced airway inflammation in
that animal model. In contrast with that study using
ST2-deficient DO11.10 Th2 cells, administration of
3E10 (anti-ST2) mAb or soluble ST2-Fc fusion protein
to mice injected with DO11.10 Th2 cells showed at-
tenuated airway function and inflammation after OVA
challenge (Table 4).19,111 If 3E10 mAb acted as an ag-
onistic Ab for Th2 cells in vivo as well as in vitro, the
phenotypes seen in mice treated with this mAb may
be consistent with the study using ST2-deficient
DO11.10 Th2 cells (Table 4),109 but inconsistent with
those treated with soluble ST2-Fc fusion protein (Ta-
ble 4) or other studies (Table 2, 3). The apparent dis-
crepancy between the study using ST2-deficient mice
and mice treated with anti-ST2 and ST2-Fc fusion pro-
teins remains to be explained. However, perhaps ST2-
expressing Th2 cells, macrophages and other im-
mune cells have different roles in the induction of al-
lergic airway inflammation, because airway eosino-
philia was observed even in mice deficient in andor
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Table 2 Airway inflammation in ST2-deficient mice
ObservationsExperimental protocolReference
- Normal eosinophil count in BALFs
- Normal pulmonary inflammation
- Normal total IgG1 and IgE in sera
129 x B6
ST2-/-mice
Hoshino K et al.
J Exp Med
190, 1541, 1999
- Normal AHR (penh and GL)
- Normal pulmonary inflammation (air-
way mucous cel hyperplasia, pul-
monary fibrosis or peribronchial cel 
inflammation)
- Normal OVA-specific cytokine secre-
tion by mediastinal LN cels in vitro
- Normal eosinophils, but reduced 
macrophages in BALFs
BALB/c
ST2-/- mice
Mangan NE et al.
Eur J Immunol
37, 1302-1312, 
2007
- Reduced eosinophils and macro-
phages in BALFs
- Reduced IL-5, but not IL-4 or IL-13, 
levels in BALFs
- Reduced pulmonary inflammation
- Normal levels of IgG1 and IgE in sera
BALB/c
ST2-/-mice
Kurowska-Stolar-
ska M et al.
J Immunol
181, 4780, 2008
- Normal responsesBALB/cST2-/-mice
Day0 12 24 26 28 30 31
Analyze
50 µg OVA in 1 mg alum i.p. 10 mg/ml OVA aerosol
30 min, 3 times at 1-h intervals
Day0 14 28 29 30 32
Analyze
20 µg OVA in 2 mg alum i.p. 1% OVA aerosol, 20 min.
Day0 8 9 10 11
Analyze
100 µg OVA in 2% alum i.p. 10 µg OVA I.n.
Day0 12 24 26 28 30 31
Analyze
100 µg OVA in 2% alum i.p. 10 µg OVA I.n.
Table 3 Efects of anti-ST2 mAb (3E10), soluble ST2 and anti-IL-33 Ab on mouse airway inflammation
ObservationsExperimental protocolReference
- Reduced eosinophil count and IL-5 
level in BALFs
- Reduced OVA-specific serum IgE 
level
Male
BALB/c-WT 
mice
Coyle AJ et al.
J Exp Med
190, 895, 1999
- Reduced AHR, mucus secretion 
and ST2+ T cel infiltration in lungs
- Reduced IL-4 and IL-13 levels in 
BALFs
- Normal IL-33 levels in lung tissues
BALB/c
WT mice
Kearley J et al.
Am J Respir Crit 
Care Med
179, 772, 2009
- Reduced eosinophils and IL-4 and 
IL-5 levels in BALFs
- Reduced OVA-specific IL-4 and IL-
5 production by spleen cels from
OVA-sensitized mice in vitro
Female 
BALB/c-WT 
mice
Oikawa K et al.
Clin Exp Alergy
32, 1520, 2002
- Reduced eosinophils and lympho-
cytes, and IL-4, IL-5 and IL-13 lev-
els in BALFs
- Reduced pulmonary inflammation
- Reduced total and OVA-specific IgE 
in sera
Female 
BALB/c-WT 
mice
Liu X et al.
BBRC
386, 181, 2009
Day0 147 21 22
Analyze
100 µg anti-ST2 mAb (clone 3E10), or control rat IgG1
1 h before OVA sensitization and challenge, route ???
20 µg OVA
in 1.5 mg alum i.p.
10 mg/ml OVA
aerosol, 1 hr.
Day0 19 232221201812 25 27 29 30
Analyze
25 µg anti-ST2 mAb (clone 3E10)
or control rat IgG i.v.
10 µg OVA
In alum i.p.
5% OVA aerosol
20 min.
Day-1 760 13 14 15
Analyze
100 µg OVA in 2 mg alum i.p.
Soluble ST2 gene transfer
1% OVA aerosol, 30 min, twice
Day0 14 25 26 27 28
Analyze
20 µg OVA
in 2 mg alum i.p.
150 µg anti-IL-33 polyclonal Ab, or control rabbit IgG I.p
30 min before OVA sensitization and challenge
1% OVA
aerosol, 30 min.
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Table 4 Efects of anti-ST2 mAb (3E10) and soluble ST2 on airway inflammation in adoptive Th2 cel transfer model
ObservationsExperimental protocolReference
- Reduced eosinophils and IL-4 and 
IL-5 levels in BALFs
BALB/c-WT 
mice
Lohning M et al.
Proc Natl Acad Sci 
USA
95, 6930, 1998 
- Reduced IL-4, IL-5, IL-6 and IL-13, 
but not IL-10 or IFN-γ, in BALFs
- Reduced eosinophil count in BALFs
- Reduced Penh responses and pul-
monary inflammation
BALB/c-WT 
mice
Coyle AJ et al.
J Exp Med
190, 895, 1999
- Exacerbated AHR and lung inflam-
mation
- Increased eosinophils in BALFs
- Increased IL-5 expression
- No diferences in lung IL-33 mRNA 
expression
- Normal OVA-specific cytokine secre-
tion by mediastinal LN cels in vitro
BALB/c-WT 
mice or 
BALB/c-Rag-
1-/- mice
Mangan NE et al.
Eur J Immunol
37, 1302-1312, 
2007
Day0 1 2 3
Analyze
50 mg/ml OVA aerosol, 20 min.
20 µg anti-ST2 mAb (clone 3E10),
ST2-IgG fusion protein or control IgG
1 h before OVA inhalation, route ??
DO11.10 Th2 cell
i.v. injection
Day0 1 2 3
Analyze
50 mg/ml OVA aerosol, 20 min.
20 or 100 µg anti-ST2 mAb (clone 3E10) ,
100 μg ST2-IgG fusion protein or control IgG
1 h before OVA inhalation, i.v. injection
DO11.10 Th2 cell
i.v. injection
Day0 10987 11 12 13 14 15
Analyze
±2 µg OVA
In alum i.p. 2% OVA aerosol, 20 min.
WT or ST2/ DO11.10 Th2 cell i.v.
depleted of T cells, B cells, mast cells, andor NK
cells after IL-33 inhalation.23 Also, excessive IL-1 pro-
duction, if it occurred in ST2-deficient mice, might
contribute to the discrepant results between the ef-
fects of genetic ST2 deficiency and protein molecules
on IL-33 signals, as mentioned before.
In addition, Rag-2-deficient mice, which lack B cells
and T cells, including ST2-expressing Th2 cells and
Tr1 cells,32 showed aggravated airway inflammation
induced by IL-33.23 Together with the study of the
adoptive Th2 cell transfer model using ST2-deficient
DO11.10 Th2 cells,109 these observations suggest
that ST2-expressing T cells have a regulatory role in
IL-33-mediated airway inflammation. On the other
hand, IL-33 can enhance the development and activa-
tion of AAMφM2a, resulting in enhanced eosino-
philic airway inflammation.72
DERMATITIS, RHINITIS, RHINOSINUSITIS AND
CONJUNCTIVITIS
In addition to in asthma, polymorphism in the ST2
andor IL-33 genes was also found in patients with
atopic dermatitis,115 rhinitis116 and rhinosinusitis.117
ST2 mRNA expression is increased in skin from rats
with contact dermatitis induced with 2,4-dinitro-
fluorobenzene.118 IL-33 mRNAprotein levels are in-
creased in specimens from patients with allergic con-
junctivitis,119 rhinitis116 and atopic dermatitis.39 These
observations suggest involvement of the IL-33-IL-33R
pathway in the development of such allergic disor-
ders.
ANAPHYLAXIS
The serum levels of IL-33 were significantly increased
in atopic patients during anaphylaxis.39 In mice, IL-33
deteriorated IgE-mediated anaphylaxis.39
IL-33-IL-33 R IN AUTOIMMUNE AND
CHRONIC INFLAMMATORY DISEASES
ARTHRITIS
The levels of soluble ST2 were increased in the
synovial fluid from patients with rheumatoid arthritis
(RA),120 which is considered to be a Th17 cell-
mediated autoimmune disorder. IL-33 mRNApro-
teins were also elevated in the sera, synovial fluid
andor inflamed lesions of the patients.5,121-123
Administration of polyclonal anti-ST2 antiserum,
which has potential activity to deplete ST2-expressing
cells, to mice resulted in exacerbation of collagen-
induced arthritis (CIA), which is considered to be a
mouse model for RA.64 On the other hand, mice
treated with soluble ST2-Fc fusion proteins or anti-
ST2 mAb and mice deficient in ST2 showed attenu-
ation of CIA,121,122,124 while mice treated with IL-33
showed aggravated disorders. These observations
suggest that certain ST2-expressing cells may act as
effector cells andor regulatory cells in the develop-
ment of CIA. In fact, ST2-expressing mast cells were
shown to act as an effector of aggravated CIA devel-
opment.121 Inhibition of IL-1 is beneficial for treat-
ment of RA,11 and inhibition of the IL-33-IL-33R path-
way may be similarly useful for therapy of this dis-
ease.
DIABETES MELLITUS (DM) AND ATHEROSCLE-
ROSIS
Diabetes mellitus (DM) is divided into insulin-
dependent DM (IDDM)type 1 DM (T1D) and non-
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insulin-dependent DMtype 2 DM (T2D). T1D,
which is due to insulin deficiency caused by destruc-
tion of beta cells in the pancreatic islets of Langer-
hans by autoreactive T cells, is considered to be a
chronic autoimmune disease.
Antibiotic streptozocin, which is an analogue of N-
acetylglucosamine (GluNAc), is transported into beta
cells via the GLUT2 glucose transporter and inhibits
the activity of O-GlcNAcase.125,126 Since metabolism
of the sugar in O-linked proteins is critical for beta
cells, inhibition of O-GlcNAcase leads to apoptosis of
beta cells.125,126 Thus, it is known that administration
of streptozocin to rodents results in symptom of
T1D.125,126 The destruction of islet beta cells during
streptozocin-induced DM is known to be mediated by
TRAIL, but not Fas.127,128 Recently, it was shown that
the development of streptozocin-induced DM was ex-
acerbated in ST2-deficient mice,129 suggesting in-
volvement of the IL-33-IL-33R pathway in the develop-
ment of human T1D.
Some patients with T2D characterized by hypergly-
cemia, and hyperinsulinemia due to insulin resis-
tance, develop atherosclerosis associated with hyper-
lipidemia. Apolipoprotein E-deficient mice spontane-
ously develop atherosclerosis that resembles human
atherosclerosis. Administration of IL-33 ameliorated
atherosclerosis development in apolipoprotein E-
deficient mice by enhancing IL-5 production and re-
ciprocally suppressing Th1 cell activity.130 On the
other hand, blockade of the IL-33-IL-33R pathway by
treatment of apolipoprotein E-deficient mice with sol-
uble ST2 resulted in exacerbated disease.130 These
observations suggest that IL-33 plays a protective role
in the development of atherosclerosis in apolipopro-
tein E-deficient mice.
ALZHEIMER’S DISEASE
In addition to the role of apolipoprotein E in athero-
sclerosis, polymorphism of the ε4 allele of the apol-
ipoprotein E gene is considered to be a genetic deter-
minant of the common forms of Alzheimer’s dis-
ease.131 As another genetic candidate, it is suggested
that SNPs at loci in regions associated with the IL-33
gene may be involved in susceptibility to non-ε4-type
Alzheimer’s disease.132
INFLAMMATORY BOWEL DISEASE
Crohn’s disease (CD) and ulcerative colitis (UC) are
representative inflammatory bowel diseases (IBD).
Soluble ST2 protein andor IL-33 mRNA were de-
tected in endothelial cells from patients with CD and
or UC,5,133,134 suggesting involvement of the IL-33-IL-
33R pathway in induction of IBD, although the pre-
cise role of IL-33 remains unclear.
Administration of dextran sodium sulfate (DSS) to
mice resulted in development of colitis associated
with destruction of colonic epithelial cells even in the
absence of T cells, B cells, NK cells and mast
cells,135-137 dependent on TLR signals.138 SIGIRR
TIR8-deficient mice showed high susceptibility to de-
velopment of DSS-induced colitis,17,139 suggesting
that signaling through IL-33-IL-33R2 is involved in
protection against colitis induced by DSS.
SYSTEMIC SCLEROSIS
IL-33 and ST2 mRNAprotein expression was in-
creased in the inflamed skin of patients with systemic
sclerosis.140 Repeated subcutaneous IL-33 injection
resulted in development of skin fibrosis similar to
that seen in patients with systemic sclerosis
(scleroderma).141 The development of IL-33-mediated
cutaneous fibrosis was dependent on IL-13 (probably
derived from eosinophils), but not IL-4, and it re-
quired eosinophils and T andor B cells, but not mast
cells.141 These observations suggest that IL-33-IL-33R
pathways may be important for induction of the skin
fibrosis seen in patients with systemic sclerosis
(scleroderma).
SYSTEMIC LUPUS ERYTHEMATOSUS
Serum levels of soluble ST2 protein were increased in
patients with systemic lupus erythematosus
(SLE).142,143 MRLlprlpr mice spontaneously develop
autoimmune diseases resembling human SLE.
SIGIRRTIR8-deficient C57BL6lprlpr mice showed
exacerbated lung disease and lupus nephritis.144
These observations suggest that the IL-33-IL-33R
pathway is involved in the development of SLE, but
the precise roles of IL-33 and IL-33Rs in that patho-
genesis remain unclear.
CARDIAC DISEASES
The serum level of soluble ST2 protein was elevated
in patients with heart failure, acute myocardial infarc-
tion, aortic stenosis and congestive cardiomyopa-
thy.145-147 In addition, IL-33 mRNAprotein was in-
duced in cardiac fibroblasts after biomechanical
stimulation.148 It was shown that mortality, cardiac fi-
brosis and cardiomyocyte hypertrophy were in-
creased in ST2-deficient mice, but decreased in mice
administered IL-33, after transverse aortic constric-
tion.148 Treatment with IL-33 reduced ventricular dila-
tion, improved contractile function and improved sur-
vival in mice after myocardial infarction by preventing
cardiomyocyte apoptosis.149 These observations sug-
gest that the IL-33-IL-33R pathway plays a regulatory
role in the induction of certain cardiac diseases.
LIVER INJURY AND FIBROSIS
Both IL-33 and ST2 mRNA were increased in fibrotic
livers of humans and mice.150 Sinusoidal endothelial
cells in the normal liver and activated hepatic stellate
cells in fibrotic livers are the main source of IL-33.150
Administration of carbon tetrachloride (CCl4) in-
duces liver injury and fibrosis in mice. In general,
treatment with soluble ST2-Fc fusion proteins re-
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sulted in inhibition of Th2-type responses such as
Th2 cytokine production. During CCl4-induced liver
injury in mice, however, soluble ST2 protein treat-
ment enhanced production of Th2 cytokines such as
IL-4 and IL-13.151 CCl4-induced liver injury developed
as usual in mice treated with soluble ST2-Fc fusion
proteins, while liver fibrosis was accelerated and en-
hanced by increased production of IL-4 and IL-13 (de-
rived from Th2 cells, not iNKT cells) in those mice.
Although the molecular mechanism of the enhance-
ment of Th2 cytokine production by soluble ST2 pro-
tein treatment in mice during CCl4-induced liver in-
jury and fibrosis remains unclear, the IL-33-IL-33R
pathway is important for the pathogenesis of liver fi-
brosis.
HYPERNOCICEPTION
Such IL-1 cytokines as IL-1 and IL-18 can provoke hy-
pernociception.152,153 Like IL-1 and IL-18, IL-33 injec-
tion can induce nociceptor sensitization (hyperno-
ciception), and IL-33 is also involved in antigen-
induced hypernociception that is dependent on TNF,
IL-1 and IFN-γ, but not IL-18.154
CONCLUSION
Although it was initially thought that IL-33 was a cru-
cial cytokine for Th2 cytokine-mediated host defense
as well as induction of Th2-type allergic disorders, it
is now known that IL-33 has a pleiotropic, not a re-
stricted, Th2 cytokine-mediated, role in various im-
mune responses as a proinflammatory cytokine, simi-
lar to IL-1 and IL-18. Therefore, IL-33 may have poten-
tial as a therapeutic target in various diseases.
Whereas the effects of IL-33 on various cell types
have been extensively investigated, further studies
are required to understand the biological significance
of IL-33, the cellular source(s) of IL-33, the mecha-
nisms involved in active IL-33 production and the role
of IL-33 as a nuclear factor.
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